Most Recent
Mail order company Magnamail has denied allegations by the Australian Competition and Consumer Commission that it sent false or misleading promotional material implying customers were eligible for major prizes if they ordered from its catalogues.
Construction PRO
A court has dismissed a bid to temporarily block a deed of company arrangement for Halo Tower developer FT Sydney, after hearing an injunction might jeopardise a sale to Cbus Property, set to settle in July.
Venture capital firm EVP has won court approval to pursue claims against bankrupt Strongroom AI founder and former director Christopher Durre.
Construction PRO
Property manager Fortius wants to add new claims under NSW's Design and Building Practitioners Act against certifier City Plan Services in a dispute over the One Central Park development in Sydney.
Construction PRO
A judge has questioned why unsecured creditors will not give a promise to pay damages as they seek to stop a DOCA for the Milligan-owned developer of the $1.8 billion Halo Tower from going ahead, which could allegedly cause $100 million in losses.
Construction PRO
Maddocks has elevated a construction partner with over 20 years of experience at the firm to serve as its next CEO.
Construction PRO
Preventing a DOCA for the Milligan-owned developer of the troubled $1.8 billion Halo Tower skyscraper in Sydney could cause $100 million in losses and jeopardise a sale to Cbus set to settle in July, a court has heard.
Construction PRO
Twenty-one former property owners at the site of the troubled 55-storey Halo Project skyscraper in the Sydney CBD have won access to a contract entered with Cbus Property shortly before developer FT Sydney went into administration.
Venture capital firm EVP has sought the court’s leave to proceed with claims against Strongroom AI founder and former director Christopher Durre, despite his financial state.
AstraZeneca has slammed Pharmacor's defence to claims it infringed a patent for blockbuster diabetes drug Forxiga as a "complete shot in the dark", as the drug maker unsuccessfully fought orders to produce documents from a UK case.